Express Scripts Realignment Identifies Non-Core Businesses
This article was originally published in The Pink Sheet Daily
Express Scripts is “looking at strategic alternatives” for some of its non-core businesses, which include international ventures, UBC and PolyMedica.
You may also be interested in...
Sanofi/Medco-UBC Evidence Partnership Includes 60 Projects Across Most Therapeutic Categories
Projects include creation of an enhanced “core value dossier” supporting reimbursement for a novel oncology drug and development of a “relative medical value index” framework to help prioritize pipeline projects and highlight opportunities to expand an individual drug study plan to address payer needs.
“The Pink Sheet” DAILY’s Most Popular Stories Last Week
Obesity and diabetes drug development and market issues drew the most attention from readers.
Genetic Testing For Tamoxifen, Warfarin, Plavix Lacks “Clear Value,” Express Scripts Says
Express Scripts’ caution about the cost effectiveness of some genetic testing could hint at how interested it will be in continuing the pharmacogenomic programs sponsored by former rival PBM Medco, which Express acquired in early April.